1. Home
  2. ONL vs VTVT Comparison

ONL vs VTVT Comparison

Compare ONL & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orion Office REIT Inc.

ONL

Orion Office REIT Inc.

HOLD

Current Price

$2.09

Market Cap

111.5M

Sector

Real Estate

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$34.00

Market Cap

127.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONL
VTVT
Founded
2021
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
111.5M
127.0M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
ONL
VTVT
Price
$2.09
$34.00
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
N/A
$51.33
AVG Volume (30 Days)
255.9K
23.8K
Earning Date
03-05-2026
11-06-2025
Dividend Yield
3.72%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$149,775,000.00
$17,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.46
$13.46
52 Week High
$4.25
$44.00

Technical Indicators

Market Signals
Indicator
ONL
VTVT
Relative Strength Index (RSI) 42.24 43.33
Support Level $2.04 $32.40
Resistance Level $2.20 $41.95
Average True Range (ATR) 0.09 3.50
MACD -0.01 -0.94
Stochastic Oscillator 18.18 6.34

Price Performance

Historical Comparison
ONL
VTVT

About ONL Orion Office REIT Inc.

Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.

Share on Social Networks: